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Abstract 
Cerebral venous thrombosis (CVT) is a distinct cerebrovascular condition that represents 
0.5–1% of all strokes in the general population. Because of its procoagulant and 
antifibrinolytic effects [Horne et al.: J Clin Endocrinol Metab 2004;89:4469–4473], 
hyperthyroidism has been proposed as a predisposing factor for CVT [Saposnik et al.: 
Stroke 2011;42:1158–1192]. For the first time, we describe a 22-year-old right-handed 
woman with a sinus sigmoideus thrombosis due to Graves’ disease. Although subclinical 
hyperthyroidism had been detected 2 years before the onset of neurological symptoms, 
she did not receive any medical follow-up. Early recognition, diagnosis and treatment are 
of crucial importance, as Graves’ disease is a risk factor for CVT and stroke. 
 
Introduction 
Cerebral venous thrombosis (CVT) is a distinct cerebrovascular condition that has an 
estimated incidence between 0.5 and 1% of all strokes in the general population. It most 
often occurs in children and young adults, with approximately 5 cases per million 
individuals annually [2]. Graves’ disease represents 50–60% of all hyperthyroidisms and is 
the most common cause of thyrotoxicosis. It is an autoimmune thyroid disorder with the 
formation of thyroid-stimulating immunoglobulins that bind to and activate thyrotropine 
receptors. This process causes growth of the thyroid gland and increases the synthesis of 
thyroid hormones. The characteristic picture of Graves’ disease is a diffusely enlarged Case Rep Neurol 2011;3:203–209 
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thyroid gland with very high radioactive iodine uptake, excessive thyroid hormone levels 
and the presence of autoantibodies directed against the thyrotropine receptor [3]. 
Hyperthyroidism is a predisposing factor for CVT in 1.7% of patients [2]. Indeed, 
because of its procoagulant and antifibrinolytic effects, hyperthyroidism is a known 
prothrombotic condition [1, 4] that has been considered an independent risk factor for 
sinus thrombosis [5]. A thorough review of the literature resulted in 20 case reports 
describing CVT [5–15] due to hyperthyroidism. Only 8 patients presented Graves’ disease 
with no risk factors other than the use of oral contraceptives and/or elevated factor VIII 
(F VIII) [9–14]. 
Here, we describe a unique patient who presented with a sinus sigmoideus thrombosis 
and an associated venous infarction in the left temporal lobe secondary to Graves’ disease. 
Case Report 
A 22-year-old right-handed woman was admitted to our hospital because of a generalized tonic-
clonic seizure. For 4 days prior to the seizure, she had been complaining of regular headache with 
vomiting. Palpitations and fatigue had also begun a couple of months earlier. Her medical history 
consisted of a splenectomy following trauma in 2000 and infectious mononucleosis in 2003. Previous 
blood tests performed in 2009 by the patient’s general practitioner were consistent with subclinical 
hyperthyroidism characterized by suppressed thyroid stimulating hormone (TSH) (<0.01 μU/ml; 
normal range = 0.30–3.90) with suppressed free T3 (fT3) (3.4 pmol/l; normal range = 4.3–8.1) and 
normal free T4 (fT4) (11.26 pmol/l; normal range = 10.0–28.2). Notwithstanding these results, the 
patient was not followed up. Vascular risk factors were limited to the intake of an oral contraceptive 
containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. There was no history of drug abuse or 
smoking, and her family history was unremarkable. Preliminary testing on admission revealed the 
following values: blood pressure 170/70 mm Hg, heart rate 134 beats per minute, eyetone 160 mg/dl and 
oxygen saturation 100%. During the immediate postictal phase, the patient was agitated and confused. 
Consciousness was clouded as well. In addition, a neurological examination revealed severe verbal 
comprehension disturbances. Oral output was limited to indifferent sounds and grunting. The patient 
presented with automatic behavior consisting of spontaneous eye opening and stereotypical movements 
of all four limbs. Plantar responses were bilaterally extensor. There was a normal response to pain. 
There was no nuchal rigidity. 
Laboratory results revealed normal blood count, kidney function and liver function. 
Electrocardiography demonstrated a sinus tachycardia. EEG showed lateralized sharp delta and theta 
waves with epileptiform discharges in the frontal, temporal and central regions of the left hemisphere. 
Polyrhythmic background activity, mainly consisting of delta waves without epileptiform discharges, 
was found over the right hemisphere. Based on these findings, a diagnosis of nonconvulsive status 
epilepticus was made. MRI of the brain showed thrombosis of the left sinus sigmoideus with a 
secondary venous infarction in the left temporal lobe with hemorrhagic conversion (fig. 1). Additional 
thyroid function tests revealed a TSH below 0.01 μU/ml, with an fT3 of 27 pmol/l and an fT4 of 77 
pmol/l. 
The patient was admitted to the intensive care unit and treatment was started with intravenous (IV) 
heparin, IV valproic acid 1,500 mg/day, methimazole 60 mg/day, IV contrast 5 ml/day, hydrocortisone 
100 mg three times/day and propranolol 40 mg three times/day. After 3 days, her clinical condition 
gradually improved. When consciousness normalized, fluent aphasia, taxonomically compatible with 
Wernicke’s aphasia, dominated the clinical picture. Speech therapy was initiated and induced a 
significant improvement of the aphasia. 
Laboratory tests for hypercoagulable state were performed before the start of heparin administration. 
The activities of proteins C and S, antithrombin III, lupus anticoagulants and F V were normal. 
Additional investigation of the patient’s thyroid gland function demonstrated an elevated titer of 
antithyroglobulin antibodies 250 U/ml (normal: <40) and anti-TPO microsomal antibodies 73 U/ml Case Rep Neurol 2011;3:203–209 
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(normal: <35) with normal TSH receptor antibodies. Thyroid scintigraphy revealed a mildly enlarged, 
diffusely captating thyroid gland. 
A diagnosis of Graves’ disease with secondary thrombosis of the left sinus sigmoideus encroaching 
upon the jugular bulb, associated with a venous infarction in the left temporal lobe, was made. 
Discussion 
This patient presented a left sinus sigmoideus thrombosis and secondary stroke due to 
Graves’ disease. Thrombosis of the cerebral veins represents 0.5–1% of all strokes, 
accounting for approximately 5 cases per million individuals annually. It is more 
commonly found in young individuals, and hyperthyroidism has been reported to be a 
predisposing factor for CVT [2]. 
Hyperthyroidism is a prothrombotic state because of its procoagulant and 
antifibrinolytic effects [1]. Higher fibrinogen, higher F VIII and plasminogen activator 
inhibitor-1 and lower protein C is typically found in patients with hyperthyroidism. Since 
F VIII promotes while protein C inhibits thrombin production, these changes are 
responsible for hypercoagulability [1]. In addition, there is also a shift towards reduced 
plasminogen activation, which is responsible for the antifibrinolytic effect [1]. 
Hyperthyroidism also induces elevation of von Willebrand factor, which is associated 
with an enhanced platelet function and, therefore, with a shortened clotting time [4]. 
After carefully reviewing the literature, only 20 case reports dealing with CVT [5–15] 
due to hyperthyroidism could be found. Only 8 patients had Graves’ disease with no risk 
factors other than the use of oral contraceptives and/or elevated F VIII [9–14]. The latter 
was only present in 3 patients [13, 14] and was not determined in our patient. In sharp 
contrast to our patient, the thrombosis did not affect the sinus sigmoideus in these other 8 
patients (table 1). The remaining 12 patients either had another etiology of their 
hyperthyroidism or other thrombophilic risk factors such as factor V Leiden mutations, 
protein C deficiency, activated protein C resistance, anticardiolipins, plasminogen 
deficiency, prothrombin G20210A mutation, atrial fibrillation or increased homocysteine 
with homozygote C6775 polymorphism of the MTHFR gene [5–9]. No causes other than 
Graves’ disease were identified to explain the hypercoagulable state in our patient. Given 
the known effects of hyperthyroidism on coagulation and platelet function, we believe 
that this was the sole cause of the thrombosis of the sinus sigmoideus. 
Our patient underwent a laboratory test in 2009 which revealed subclinical 
hyperthyroidism. The definition of subclinical hyperthyroidism is a serum TSH 
concentration below the statistically defined lower limit of the reference range, with 
serum fT4 and fT3 concentrations within their reference ranges [16]. When the lower 
limit of TSH is defined as <0.4 mIU/l, the prevalence of hyperthyroidism is 3.2% [16].The 
prevalence of hyperthyroidism decreases to 0.7% at a TSH level <0.1 mIU/l [16]. Each 
year, 1–2% of patients with subclinical hyperthyroidism and a suppressed TSH level <0.01 
μU/ml progress to overt hyperthyroidism [16, 17]. When the serum TSH concentration 
drops below 0.10 μU/ml, a repeat serum test should be performed within 4 weeks. If TSH 
levels remain between 0.10 and 0.45 μU/ml, or dip below 0.10 μU/ml, further 
investigation is required [16, 17]. If further investigations in our patient had been 
performed during the phase of subclinical hyperthyroidism, early diagnosis and treatment 
might have prevented the complications of CVT and stroke. Case Rep Neurol 2011;3:203–209 
DOI: 10.1159/000331448 
Published online: 
September 7, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–680X 
www.karger.com/crn   
 
 
 
206
Our patient took an oral contraceptive containing ethinyl estradiol 0.02 mg and 
drospirenone 3 mg. Ethinyl estradiol is an orally bioactive estrogen. Drospirenone is a 
synthetic progestin that has antimineralocorticoid properties. The intake of oral 
contraceptives is linked to an increased risk of venous thrombosis. The use of oral 
contraceptives is also associated with increased prothrombin, F VII, F VIII, F X, 
fibrinogen, increased levels of prothrombin fragments 1 and 2, and a decreased F V level, 
which suggests a procoagulant effect. In addition, there is an acquired resistance to 
activated protein C, causing a decrease in anticoagulation. This results in a net 
prothrombotic effect [18]. Recent studies suggest that oral contraceptives containing 
ethinyl estradiol and drospirenone are associated with a 2- to 3-fold increase in the risk of 
venous thromboembolism in comparison to second generation oral contraceptives 
containing levonorgestrel. Although currently considered the preferred choice, oral 
contraceptives containing levonorgestrel are known to carry a 4-fold increase in the risk 
of venous thromboembolism in users versus non-users. These studies, however, did not 
involve patients with sinus thrombosis. Further investigation is required to determine the 
importance of oral contraceptive use as a risk factor for CVT [19]. 
Conclusion 
We describe a 22-year-old right-handed female patient with a left sinus sigmoideus 
thrombosis and secondary infarction in the left temporal lobe as the presenting symptoms 
of Graves’ disease. A concise survey of the literature shows that this localization has not 
been described before in patients with Graves’ disease without other risk factors. 
Hypercoagulable findings clearly demonstrate the importance of early recognition and 
follow-up of subclinical and overt hyperthyroidism, since it is a known independent risk 
factor for sinus thrombosis. Early diagnosis and treatment may prevent serious 
neurological complications such as CVT and stroke. 
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Table 1. Overview of 8 patients with CVT due to hyperthyroidism 
Patient Sex  Age 
years 
Site of thrombosis  Thyroid disease  Other risk factors  Reference
1  M  24  Superior sagittal sinus  Graves’ disease  No thrombophilia 
No atrial fibrillation 
10 
2  F  32  Superior sagittal sinus 
Left transverse sinus 
Graves’ disease  No thrombophilia 
No atrial fibrillation 
10 
3 F  18  Deep  cerebral  veins 
Inferior sagittal sinus, straight sinus, 
left lateral sinus 
Graves’ disease  No thrombophilia, low-dose 
oral contraceptive pill 
11 
4  F  38  Left lateral sinus  Graves’ disease  No thrombophilia  12 
5  F  44  Longitudinal superior sinus, 
right lateral sinus 
Not specified  No protein C or S deficiency  12 
6  F  39  Left lateral sinus 
Left jugular vein 
Graves’ disease  Oral contraceptive pill 
Increased F VIII 
13 
7  F  50  Left parietal cortical vein 
Left lateral sinus 
Graves’ disease  Oral contraceptive pill 
Increased F VIII 
14 
8  F  38  Superior longitudinal sinus, 
right lateral sinus 
Graves’ disease  Oral contraceptive pill 
Increased F VIII 
14 
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Fig. 1. (a–d) Cranial MRI in the axial plane: a Diffusion-weighted sequence revealing mixed high- and 
low-signal lesions indicating ischemic stroke with hemorrhagic transformation. FLAIR (b) and FSE T2-
weighted images (c) showing the venous infarction in the left temporal lobe and the presence of blood 
in the Sylvian sulcus. d Gadolinium-enhanced T1 sequence revealing a complete thrombosis of the left 
sinus sigmoideus. 
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